{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Clinical benefit will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of minimal response (MR) or better as determined by the IMWG criteria","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5m Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10 mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15 mg Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Participants who initiate protocol-directed therapy and have measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"participants"}